°®×öÃÎ
£¿Ð¡ÐÄ£¡¿ÉÄÜÊǼ²²¡ÔÚÔ¤¾¯£¡

½ÒÏþÔÚȨÍþÔÓÖ¾¡¶ÁøÒ¶µ¶¡·×Ó¿¯µÄ¶àÏîÑо¿·¢Ã÷£¬È˵ÄÃÎÏ羹ȻºÍ¼²²¡Ï¢Ï¢Ïà¹Ø£¡ÓÈÆäÊÇ8ÖÖÃÎÏç£¬ÌáÐÑ¿Ö²À¼²²¡£¡

8ÖÖÃÎÏç£¬ÌáÐÑ¿Ö²ÀµÄ¼²²¡£¡

1¡¢Ãε½±»ÈË׷ɱ£¬²¢Åãͬȭ´ò½ÅÌß

Èý¸ü»áͻȻ¾ªÐÑ£¬ÑÛ¾¦µÉµÃ¼«´ó£¬ÄÔº£ÀïÃÎÏçµÄ»­ÃæÊ®·ÖËÕÐÑ¡£ÌìÌì×öµÄÃζ¼²îδ¼¸£¬²»ÊDZ»¿Ö²ÀµÄÒ°ÊÞ×·¸Ï¡¢¾ÍÊDZ»ÈË׷ɱ¡£¾ÍËãÊÇÈýÄêÇ°µÄÃÎ£¬Ò²ÄÜ°Ñϸ½Ú¼ÇµÃÇåÇåÎú³þ¡­¡­ÔÚ˯ÃßÖÐÉõÖÁ»áº°½Ð¡¢×çÖä¡¢»ÓÎè×ÅÊÖ±Û¡¢ÊÔͼץÎÕסÎäÆ÷£¬¶Ô×Å¿ÕÆøÈ­´ò½ÅÌß¡­¡­ÔÚÕâ¸öÀú³ÌÖÐ£¬Ãâ²»Á˻᷺Æð×Ô¼ºµøÏ´²µÄÊÂÇé¡£ÉõÖÁÓÐʱ¼ä£¬ÕæµÄ»áÔÚÃÎÖÐÏ´²£¬ÍÑÀë×Ô¼ºµÄÎÔÊÒ£¬ÏñÊÇÒ»³¡¿Ö²ÀµÄVRÌåÑé¡­¡­

¶øÕâÖÖÕæʵ¸Ð¼«Ç¿£¬²¢°éÓÐÈ­´ò½ÅÌߵĶñÃÎ£¬¾¹È»»áÌáÐÑÅÁ½ðÉ­²¡£¡

Ô­À´£¬¾­³£×öÕâÖÖ¶ñÃÎ£¬ÊÇÒ»ÖÖ˯Ãß¼²²¡£¬½Ð×ö¿ìËÙÑÛ¶¯ÆÚ˯ÃßÕÏ°­£¬ÕâÊÇÒ»ÖÖÉñ¾­ÍËÐÐÐÔ¼²²¡¡£ÓÐÑо¿·¢Ã÷£¬ÔÚ×öÕâÖÖ¶ñÃεÄ2Äêºó£¬¾Í»áÓÐÒ»¶¨±ÈÀýµÄÈË·ºÆðÅÁ½ðÉ­²¡µÄÖ¢×´£¬¶øÔÚ×öÕâÖÖ¶ñÃεÄ14Äêºó£¬ÓÐ81%µÄÈ˶¼È·ÕïÁËÅÁ½ðÉ­²¡£¡

2¡¢Ãε½×Ô¼º×ª¶¯²»µÃ

Ðí¶àÈ˶¼ÂÄÀú¹ý¡°¹íѹ´²¡±£¬¾ÍÊÇ´óÄÔËÕÐÑÁË£¬¿ÉÊÇ×Ô¼ºÈ´×ª¶¯²»µÃ¡£ÕâËäÈ»²»ÊÇÁéÒìÕ÷Ïó£¬¶øÊÇÒ»ÖÖ¼²²¡£ºË¯Ãß̱»¾Ö¢¡£

˯Ãß̱»¾Ö¢±¬·¢ÔÚ½«ÐÑδÐÑʱ£¬»¼Õß¾­³£¸ÐÊÜ×Ô¼º¸Õ¸ÕÐѹýÀ´£¬¿ÉÒÔÕö¿ªË«ÑÛ²¢¿´µ½ÖÜΧÊÂÎïµÄÓ°ÏñÒÔ¼°Ìýµ½ÖÜΧµÄÉùÒô£¬¿ÉÊÇÎÞ·¨Òƶ¯Çû¸ÉºÍËÄÖ«£¬Ò²ÎÞ·¨±¬·¢ÉùÒô£¬ÓÐʱ»á±¬·¢»Ã¾õ²¢¿´µ½ÐéÄâµÄÓ°Ïñ£¬ÑÏÖصIJ¡Àý»á¸ÐÓ¦ºôÎüÄÑÌâ¡£

˯Ãß̱»¾Ö¢±¬·¢ÔÚ¸Õ½øÈë˯Ãßʱ£¬»¼Õß³£°éÓпֻű¬·¢£¬×î×îÏÈ´¦ÓÚÓÐÒâʶµÄ״̬£¬µ«È´ÅãͬÌý¾õºÍÊÓ¾õÉϵĻþõ£¬È»ºóÐìÐì½øÈë¡°ÃÎÏ硱¡£

˯Ãß̱»¾Ö¢Í¨³£»¹»á°éÓС°¼ÙÐÑ¡±£¬¼´ÈËÐѹýÀ´£¬·¢Ã÷×Ô¼ºÔ­À´»¹ÔÚÃÎÀï£¬ÏÖʵÖÐÒ²»¹ÔÚ˯Ãß¡£ÕâÑùµÄ¡°¼ÙÐÑ¡±Í¨³£»á¶à´ÎÖظ´£¬ÅãͬµÄÉÐÓÐÀ´×ÔÓÚ¶ÔÕâÖÖÎÞÖÕÖ¹Öظ´µÄ¿Ö¾å¡£

3¡¢Ãε½ÄçË®¡¢ÖÏÏ¢

ÈôÊǾ­³£·ºÆðÄçË®¡¢ÖÏÏ¢µÈÎÞ·¨ºôÎüµÄÃÎÏç£¬ÐèҪСÐÄÊÇ·ñÊÇ˯ÃߺôÎüÔÝÍ£Ëùֵġ£ÈôÊÇ»¼ÓÐ˯ÃߺôÎüÔÝÍ£µÄ¼²²¡£¬ÈËÔÚÍíÉÏ˯ÃßµÄʱ¼ä¾Í»á·ºÆðȱÑõµÄÌåÏÖ£¬ÔÚÃÎÏçÉÏÒ²»áÌåÏÖ³öÄçË®¡¢ÖÏÏ¢µÈȱÑõµÄÇé¾³£¬À´ÌáÐѸ÷ÈË¿ÉÄÜÉíÌåºÍ´óÄÔÒѾ­È±ÑõÁË¡£

4¡¢Ãε½±»ÈË×·Öð£¬ÐÑÀ´ÐÄÌø¼ÓËÙ

Ðí¶àÈË¿ÉÄÜÃε½ÁËÔÚÃÎÀï±»×·Öð£¬Ë¯ÐÑ»áÓÐÐÄÌø¼ÓËÙ¡¢³öº¹¡¢ÐļµÄÇéÐÎ£¬ÕâÖÖÇéÐÎ×ÅʵºÍ´óÄÔҲϢϢÏà¹Ø£¡ÈôÊÇÒ»Ñùƽ³£Ñ¹Á¦¹ý´ó£¬´óÄÔÌ«¹ýÖ÷Òª£¬¾Í¿ÉÄܵ¼ÖÂ×öÈÃÈËÐÄÌø¼ÓËٵĶñÃΡ£ÈôÊÇÓйÚ×´¶¯Âö¹©ÑªÈ±·¦µÄÎÊÌâ£¬Í¬Ñù¿ÉÄÜ»áÔÚ˯Ãßʱ·ºÆðÐÄÂʼÓËÙµÄÇéÐΡ£

5¡¢Ãε½Í·±»Çôò

ÈôÊÇ»¼ÓÐÄÔ²¿Ö×Áö»òÉñ¾­ÏµÍ³¼²²¡£¬¾Í¿ÉÄܻᾭ³£Ãε½Í·±»Çôò»òÕßÓйÖÎïÏòÎå¹Ù¹àË®£¬ÈôÊÇÕâ¸öÃÎÏç¾­³£±¬·¢£¬½¨ÒéÈ¥Ò½Ôº¼ì²é×Ô¼ºµÄ´óÄÔÊÇ·ñ±£´æÉñ¾­ÏµÍ³µÄÎÊÌâ»ò³¤ÁËÖ×Áö¡£

6¡¢Ãε½ÑÀµôÁË

½¹Âdz£¼ûµÄÌåÏÖÊÇÖ÷Òª¡¢¿Ö»ÅºÍÑÀ³Ý´ò²ü¡£ÈôÊÇÃμûÑÀµôÁË£¬¿ÉÄÜÊÇDZÒâʶ½¹ÂÇÇéÐ÷µÄÑÓÉì£¬Ò²¿ÉÄÜÅú×¢ÄãÏ롰ҧס¡±ÏÖʵÖÐÄÑÌâµÄÇéÐÎ£¬ÈÃ×Ô¼º²»ÔÙ½¹ÂÇ¡£

7¡¢Ãε½Æ÷¹Ù±»Ç¿ÁÒ¹¥»÷

ÈôÊÇÔÚ×öÃεÄʱ¼ä£¬Ãε½×Ô¼ºµÄÐÄÔà¡¢ÉöÔà¡¢¸ÎÔàµÈλÖñ»ºÝºÝͱÁËÒ»µ¶£¬ÕâÖÖÆ÷¹Ù±»Ç¿ÁÒ¹¥»÷µÄÃÎÏç£¬¿ÉÄÜÊÇÆ÷¹ÙÔÚÌáÐÑ×Ô¼º£¬Æ÷¹ÙÉú²¡ÁË£¬Õâʱ¼ä¾ÍÐèÒª¹Ø×¢Ò»ÏÂÕâ¸öÆ÷¹ÙµÄ¿µ½¡£¬ÐëҪʱÐèҪȥҽԺ¼ì²é¸ÃÆ÷¹ÙµÄ¿µ½¡×´Ì¬¡£

8¡¢Ãε½Ï£ÆæµÄÉùÒô

Ðí¶àÈ˵ÄÃÎÏ綼ÊÇÎÞÉùµÄ£¬ÈôÊÇ×ÜÔÚÃÎÖÐÌýµ½ÒìÏì¡¢ÆæÏ£ÐÂÏʵÄÉùÒô£¬ÄÇô¾ÍÐèҪСÐÄÊÇ·ñÊÇÌý¾õÖÐÊà±£´æ²¡±äÁË¡£

ÕâÖÖʳÎï£¬¿ÉÒÔÑÓ»º´óÄÔÐàÂõ£¬Ô¤·À´óÄÔÉñ¾­ÍËÐÐÐÔ¼²²¡£¡

Ñо¿ÏÔʾ£¬Ï£ÆæµÄÃÎÏçºÍ´óÄÔÉñ¾­ÏµÍ³µÄ¼²²¡¹Øϵ¸üΪÇ×½ü£¬ÒÔÊÇÈôÊǾ­³£×öÏ£ÆæµÄ¶ñÃÎ£¬½¨Òé¸÷ÈËҪСÐÄ´óÄÔµÄÖÖÖÖÍËÐÐÐÔ¼²²¡£¬ÈçÍíÄêÐÔ³Õ´ô¡¢ÅÁ½ðÉ­²¡µÈ£¡

À´×Ô±öÖÝ´óѧÓë¹þ·ð´óѧÑо¿ÍŶÓÕë¹ØÓÚ1200Ãû»¼ÕßÕö¿ªÁè¼Ý30ÄêµÄ×·×ÙÑо¿·¢Ã÷£¬¶à³ÔÒ»ÀàÒûʳ£¬²»µ«¿ÉÒÔÈÃÅÁ½ðÉ­²¡»¼ÕߵĴæ»îÂÊÌá¸ß70%£¬»¹ÄÜÆðµ½Ô¤·ÀÅÁ½ðÉ­²¡¡¢±£»¤´óÄÔµÄ×÷Óã¡

½ÒÏþÔÚOxidative Medicine and Cellular LongevityµÄÑо¿Ò²·¢Ã÷£¬ÕâÀàʳÎï¹ØÓÚÔ¤·ÀÍíÄêÐÔ³Õ´ôÒ²ÓкܺõÄ×÷Óá£

ÕâÀàʳÎï¾ÍÊǸ»º¬»ÆͪÀ໯ºÏÎïµÄʳÎ»ÆͪÀ໯ºÏÎï×÷ΪһÖÖ×ÔÈ»µÄ¿¹Ñõ»¯¼Á£¬Æ俹Ñõ»¯×ÔÓÉ»ùµÄ×÷ÓûúÖÆÓë·ÓÀàÎïÖÊÏàËÆ£¬¶¼ÊÇÓë×ÔÓÉ»ùÍŽá£¬Æ𵽿¹Ñõ»¯×÷Óá£»ÆͪÀ໯ºÏÎï¿ÉÓëÖ¬ÀàÎïÖÊ·´Ó¦£¬½«ÇâתÒƸøÖ¬ÀàÎïÖÊ×ÔÓÉ»ùºó×ÔÌå̬³ÉÎȹ̵ķӻù×ÔÓÉ»ù£¬´Ó¶øÒÖÖÆÑõ»¯·´Ó¦µÄ¼ÌÐø¾ÙÐС£

ÒÔÊÇ»ÆͪÀ໯ºÏÎï¹ØÓÚ¶Ô¿¹´óÄÔµÄÑ×Ö¢ºÍÑõ»¯£¬¶¼ÓкܺõĹ¦Ð§£¡

Õã½­´óѧҽѧԺÑо¿ÍŶӽÒÏþÔÚ¹ú¼Ê¶¥¼âҽѧÆÚ¿¯ÃÀ¹úҽѧѧ»áÔÓÖ¾×Ó¿¯µÄÑо¿ÂÛÎÄ£¬Í¨¹ý2192ÀýÅÁ½ðÉ­²¡»¼ÕßÓë54ÓàÍò¿µ½¡ÈËȺ±ÈÕÕÜöÝÍÆÊÎöÑо¿·¢Ã÷£¬ÓÐÒ»ÖÖÔ˶¯¶ÔÑÓ»º´óÄÔÐàÂõ×îÓÐÓÃ£¬ÕâÖÖÔ˶¯¾ÍÊÇÖеÈÇ¿¶ÈÔ˶¯£¨Ô˶¯µÄÐÄÂʼá³ÖÔÚ×î´óÐÄÂÊÖµµÄ60%~80%£©£¡

ÔõÑùÅжÏ×Ô¼ºµÄÐÄÂÊÊÇȼ֬ЧÂÊ×î¸ßµÄÐÄÂÊÄØ
£¿×ÅʵֻÐèÒªÓÃ220¼õÈ¥×Ô¼ºµÄÄêËê£¬¾Í¿ÉÒÔÅÌËã³öÀ´£¡ºÃ±È£ºÒ»¸ö22ËêµÄÈË£¬ËûµÄ×î´óÐÄÂʾÍÊÇ220-22£¬Ò²¾ÍÊÇ198¡£

¡¶·ï»Ë´ó¿µ½¡¡·Ò½Ñ§×éÒ²¸ø¸÷ÈËÍƼöÒ»¸öÔÚ¼Ò¾ÍÄÜ×öµÄÖеÈÇ¿¶ÈÔ˶¯---³¬ÂýÅÜ£¡³¬ÂýÅÜÊÇÒ»ÖÖÈø÷ÈËÔÚ180²½/·ÖÖӵIJ½ÆµÏ¾ÙÐеÄÂýÅÜÔ˶¯¡£

ÔÚ³¬ÂýÅܵÄʱ¼ä£¬ÐèҪעÖز½ÆµÒª¿ì¡¢²½·ù²»Òª´ó£¬½ÅÕÆÒªÇáÇá×ŵØ£¬ÒÔ¼õÇá¶ÔÏ¥¸ÇµÄËðÉË¡£¸÷ÈË¿ÉÒÔÔÚ¼ÒÔ­µØ³¬ÂýÅÜ£¬Ò²¿ÉÒÔ³öÞÙÐг¬ÂýÅÜ¡£ÈôÊÇÊÇÍíÄêÈË£¬¿ÉÒ԰Ѳ½Æµ½µµ½130-140²½/·ÖÖÓ¡£

½¨Òé¸÷ÈËÿÖܾÙÐÐ3-4´ÎµÄ³¬ÂýÅÜ£¬Ã¿´Î³¬ÂýÅܾÙÐÐ40-60·ÖÖÓ¡£

²Î¿¼ÎÄÏ×£º

[1] Zhang X, Molsberry SA, Yeh TS, Cassidy A, Schwarzschild MA, Ascherio A, Gao X. Intake of Flavonoids and Flavonoid-Rich Foods and Mortality Risk Among Individuals With Parkinson Disease: A Prospective Cohort Study. Neurology. 2022 Mar 8;98(10):e1064-e1076. doi: 10.1212/WNL.0000000000013275. Epub 2022 Jan 26. PMID: 35082171; PMCID: PMC8967390.

[2] Fang X, Han D, Cheng Q, Zhang P, Zhao C, Min J, Wang F. Association of Levels of Physical Activity With Risk of Parkinson Disease: A Systematic Review and Meta-analysis. JAMA Netw Open. 2018 Sep 7;1(5):e182421. doi: 10.1001/jamanetworkopen.2018.2421. PMID: 30646166; PMCID: PMC6324511.

[3] Sloan, M., Bourgeois, J. A., Leschziner, G., Pollak, T. A., Pitkanen, M., Harwood, R., Bosley, M., Bortoluzzi, A., Andreoli, L., Diment, W., Brimicombe, J., Ubhi, M., Barrere, C., Naughton, F., Gordon, C., & D¡¯Cruz, D. (2024). Neuropsychiatric prodromes and symptom timings in relation to disease onset and/or flares in SLE: results from the mixed methods international INSPIRE study. eClinicalMedicine, [102634]. https://doi.org/10.1016/j.eclinm.2024.102634

[4] Otaiku DAI. Distressing dreams and risk of Parkinson's disease: A population-based cohort study. EClinicalMedicine. 2022 Jun 8;48:101474. doi: 10.1016/j.eclinm.2022.101474. PMID: 35783487; PMCID: PMC9249554.

[5] Minocha T, Birla H, Obaid AA, Rai V, Sushma P, Shivamallu C, Moustafa M, Al-Shehri M, Al-Emam A, Tikhonova MA, Yadav SK, Poeggeler B, Singh D, Singh SK. Flavonoids as Promising Neuroprotectants and Their Therapeutic Potential against Alzheimer's Disease. Oxid Med Cell Longev. 2022 Aug 28;2022:6038996. doi: 10.1155/2022/6038996. PMID: 36071869; PMCID: PMC9441372.